• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, September 29, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Anti-sedative could alleviate cancer therapy side effects, study suggests

Bioengineer by Bioengineer
September 20, 2022
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy. The study, published September 20 in the Journal of Experimental Medicine (JEM), suggests that the FDA-approved anti-sedative flumazenil, which targets GABAA receptors, could alleviate some of the common gastrointestinal side effects, such as diarrhea and vomiting, induced by many cancer treatments.

GABAA receptor inhibition protects the small intestine

Credit: © 2022 Zhang et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20220541

Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy. The study, published September 20 in the Journal of Experimental Medicine (JEM), suggests that the FDA-approved anti-sedative flumazenil, which targets GABAA receptors, could alleviate some of the common gastrointestinal side effects, such as diarrhea and vomiting, induced by many cancer treatments.

Because they have to continually proliferate and replace the cells lining the wall of the gut, intestinal stem cells are highly sensitive to chemotherapy and radiotherapy. These treatments damage the DNA of intestinal stem cells and cause them to die, leading to intestinal injury and a variety of painful gastrointestinal symptoms. These toxic side effects, which can persist long after treatment is finished, limit the drug or radiation dose that can be given to cancer patients and worsen their quality of life.

A research team led by Dawei Chen and Jingxin Li at Cheeloo College of Medicine, Shandong University, discovered that the levels of a protein called GABRA1 increase in the intestinal stem cells of mice treated with either radiation or a chemotherapy drug. GABRA1 is a component of the GABAA receptor, which is best known for its role in the nervous system, where it binds to the neurotransmitter g-aminobutyric acid (GABA). But GABA and the GABAA receptor are also present in other tissues throughout the body.

The researchers found that inhibiting the GABAA receptor protected mice from the toxic side effects of chemo- or radiotherapy, reducing the amount of DNA damage and increasing the survival of intestinal stem cells. This enabled the mice to maintain a normal gut lining and survive lethal doses of irradiation or chemotherapy drugs.

Chen and colleagues found that inhibiting the GABAA receptor protects intestinal stem cells from DNA damage by limiting the formation of free radicals in response to chemoradiotherapy. Crucially, however, the researchers determined that inhibiting the GABAA receptor does not prevent radiation or chemotherapy drugs from killing cancer cells.

Flumazenil is a cheap, GABAA receptor inhibitor approved by the U.S. Food and Drug Administration to treat benzodiazepine overdoses and reverse anesthesia. Chen and colleagues found that flumazenil was also able to protect the intestines of mice from the toxic effects of chemoradiotherapy. Moreover, flumazenil also protected human colonic organoids—miniature organs grown in the lab from human colonic stem cells—from chemotherapy drugs and irradiation.

“Taken together, our data suggest that inhibiting the GABAA receptor is a promising strategy to specifically protect the intestine from chemoradiotherapy,” Chen says. “Future studies are required to investigate the pharmacodynamics and tolerability of flumazenil in cancer patients undergoing treatment in the clinic.”

 

Zhang et al. 2022. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20220541?PR

 

# # #

 

About Journal of Experimental Medicine

Journal of Experimental Medicine (JEM) publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEM is published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.



Journal

Journal of Experimental Medicine

DOI

10.1084/jem.20220541

Method of Research

Experimental study

Subject of Research

Animals

Article Title

Inhibition of GABAA receptors in intestinal stem cells prevents chemoradiotherapy-induced intestinal toxicity

Article Publication Date

20-Sep-2022

COI Statement

C. Zhang reported a patent to CN202210946395.9
pending. J. li reported a patent to CN202210946395.9 pending. D.
Chen reported a patent to CN202210946395.9 pending. No other
disclosures were reported.

Share22Tweet14Share4ShareShareShare3

Related Posts

Kaylie Cullison

True progression or pseudoprogression in glioblastoma patients?

September 29, 2023
Person in CT machine

University of Cincinnati radiation oncology experts present at national conference

September 29, 2023

Research Highlights for September 2023

September 29, 2023

MSK Research Highlights September 29, 2023

September 29, 2023

POPULAR NEWS

  • blank

    Microbe Computers

    59 shares
    Share 24 Tweet 15
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    35 shares
    Share 14 Tweet 9
  • Fossil spines reveal deep sea’s past

    34 shares
    Share 14 Tweet 9
  • Scientists go ‘back to the future,’ create flies with ancient genes to study evolution

    75 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New study will examine irritable bowel syndrome as long COVID symptom

True progression or pseudoprogression in glioblastoma patients?

Neural activity associated with motor commands changes depending on context

Subscribe to Blog via Email

Oops! It seems you have several subscriptions pending confirmation. You can confirm or unsubscribe some from the Subscriptions Manager before adding more.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 56 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In